

## Part VI: Summary of the risk management plan

### Summary of risk management plan for <invented name> (Noradrenaline)

This is a summary of the risk management plan (RMP) for <invented name>. The RMP details important risks of <invented name>, how these risks can be minimised, and how more information will be obtained about <invented name>'s risks and uncertainties (missing information).

<Invented name>'s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how <invented name> should be used.

#### I. The medicine and what it is used for

<invented name> is indicated:

- for the emergency restoration of blood pressure in cases of acute hypotension (1 mg/mL dosage), and
- in adults weighing over 50 kg for the on-going treatment of hypotensive emergencies with escalating noradrenaline dose requirements (0.25 mg/mL dosage).
- in adults weighing over 50 kg for the treatment of hypotensive emergencies (0.08 mg/mL dosage).

It contains Norepinephrine as the active substance, and it is given by intravenous infusion.

#### II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of <invented name>, together with measures to minimise such risks and the proposed studies for learning more about <invented name>'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of <invented name>, these measures are supplemented with *additional risk minimisation measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of <invented name> is not yet available, it is listed under 'missing information' below.

## ***II.A List of important risks and missing information***

Important risks of <invented name> are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of <invented name>. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

*Table 6: List of important risks and missing information*

<b>List of important risks and missing information</b>	
Important identified risks	Necrosis and Peripheral ischaemia (including gangrene of the extremities)
Important potential risks	Risk of medication error [Noradrenaline 0.25 mg/mL] Risk of medication error [Noradrenaline concentrated presentation 1 mg/mL]
Missing information	None

## ***II.B Summary of important risks***

*Table 7: Summary of important risks*

<b>Important identified risk: Necrosis and Peripheral ischaemia (including gangrene of the extremities)</b>	
Evidence for linking the risk to the medicine	Literature data, safety database, Eudravigilance.
Risk factors and risk groups	Not applicable.
Risk minimisation measures	Routine risk minimisation measures - SmPC, PIL Additional risk minimisation measures - None
Additional pharmacovigilance activities	Additional pharmacovigilance activities: - None

<b>Important potential risk: Risk of medication error [Noradrenaline 0.25 mg/mL]</b>	
Evidence for linking the risk to the medicine	Post-marketing data and benefit risk balance analysis.
Risk factors and risk groups	Not applicable.
Risk minimisation measures	<p>Routine risk minimisation measures</p> <ul style="list-style-type: none"> <li>- Labelling</li> <li>- Item under close monitoring</li> </ul> <p>Additional risk minimisation measures</p> <ul style="list-style-type: none"> <li>- DHPC letter</li> </ul>
Additional pharmacovigilance activities	<p>Additional pharmacovigilance activities:</p> <ul style="list-style-type: none"> <li>- None</li> </ul>

<b>Important potential risk: Risk of medication error [Noradrenaline concentrated presentation 1 mg/ml]</b>	
Evidence for linking the risk to the medicine	Post-marketing data and benefit risk balance analysis.
Risk factors and risk groups	Not applicable.
Risk minimisation measures	<p>Routine risk minimisation measures</p> <ul style="list-style-type: none"> <li>- Labelling</li> </ul> <p>Additional risk minimisation measures</p> <ul style="list-style-type: none"> <li>- None</li> </ul>
Additional pharmacovigilance activities	<p>Additional pharmacovigilance activities:</p> <ul style="list-style-type: none"> <li>- None</li> </ul>

## ***II.C Post-authorisation development plan***

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of <invented name>.

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for <invented name>.